#Tepotinib
LightNews LightNews
oncbrothers.bsky.social
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
rolfolab.bsky.social
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
May 5, 2025 at 1:52 PM
prof-ali-g.bsky.social
With apologies to Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿 for ignorance looks like similarly to England 🏴󠁧󠁢󠁥󠁮󠁧󠁿 tepotinib available independent of line; although I would recommend as 1st line treatment as discussed
December 11, 2024 at 9:25 PM
swog.org
Lung-MAP sub-study S1900K has expanded eligibility to include treatment-naive patients. Pts w any # of previous lines of therapy (incl. ZERO -- i.e., newly diagnosed) with MET exon 14 skipping+ #NSCLC (Stage IV or recurrent) may now be eligible. Randomized to tepotinib w/wo ramucirumab. #lcsm
Lung-MAP S1900K
March 4, 2025 at 7:10 PM
icrdduiit.bsky.social
Our Investigator Initiated Trial, POTENT, presented at #ELCC2025 by Dr Anna Minchom combines tepotinib + pembrolizumab to tackle immune resistance in NSCLC.
Promising early results prelude to expanding treatment options & improving outcomes for NSCLC patients.

#LungCancer #DDUIIT
April 25, 2025 at 3:01 PM
letsmeds.bsky.social
Buy Affordable Quality Tepotinib Tablets Online
Our team is always online to assist you.
• Call/WhatsApp/Viber: +91-7428091874
• Email: letsmeds@gmail.com
• Teams & WeChat: Letsmeds

www.letsmeds.com/tepotinib-ta...

LetsMeds – Care that crosses borders. Order now and save on your treatment!
Buy Affordable Quality Tepotinib Tablets Online
June 15, 2025 at 12:09 PM
onclive.bsky.social
Pooled Analysis Shows Manageable Safety Profile With Tepotinib in MET Exon 14+ NSCLC @vallhebron.com @iaslc.bsky.social #WCLC25 #lcsm #oncology
www.onclive.com/view/pooled-...
Pooled Analysis Shows Manageable Safety Profile With Tepotinib in MET Exon 14+ NSCLC
Tepotinib treatment was characterized by frequent but manageable TRAEs in MET exon 14–positive NSCLC, with peripheral edema as the most common toxicity.
www.onclive.com
September 9, 2025 at 3:49 PM
onco404.bsky.social
Key Highlights
✅ MET inhibitors like capmatinib, tepotinib, and crizotinib are showing promising response rates (ORR up to 68.8% in trials!), outperforming traditional chemo and immunotherapy in MET-driven cases.

#Onco404 #Cancer #Oncology #NSCLC #LungCancer #oncsky #medsky
April 2, 2025 at 10:20 AM
edmonstone.net
It would be pretty straightforward to reproduce this work for other oncogene-driven NSCLC types, such as RET (Selpercatinib); NTRK (Entrectinib/Larotrectinib); KRAS (Sotorasib); METex14 (Tepotinib); ROS1 (Crizotinib/Entrectinib) or EGFR (Afatinib/Dacomitinib/Erlotinib/Gefitinib/Osimertinib)
June 10, 2025 at 3:35 PM
icrdduiit.bsky.social
🚀 Trial Opportunity! Phase I POTENT trial is recruiting at 4 UK sites—evaluating tepotinib (MET inhibitor) + pembrolizumab (immunotherapy) in NSCLC.
🔍 We warmly invite clinicians to refer suitable patients!
📄 More info: clinicaltrials.gov/NCT05782361
#LungCancer #ClinicalTrials
ClinicalTrials.gov
clinicaltrials.gov
May 2, 2025 at 2:33 PM
onco404.bsky.social
✅ Amivantamab (EGFR/MET bispecific antibody) + chemo boosted PFS in MARIPOSA-2.
✅ HER3-DXd ADCs and MET inhibitors (e.g., tepotinib) tackle off-target resistance.

📍 While hurdles like toxicity and clonal evolution persist, phase I/II data hint at a brighter future for patients 🌟

#Onco404 #MedSky
April 7, 2025 at 4:09 PM
drjkyl.bsky.social
Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer
@tamedoncol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#NSCLC #oncology #cancerresearch #cancertreatment #openaccess
August 21, 2026 at 10:22 PM
survivornetca.bsky.social
Have non-small cell lung cancer with a MET exon 14 skipping alternation? Experience with tepotinib/TEPMETKO as a treatment? Help inform a funding review via survey: surveymonkey.com/r/LCtepotini or interview: winky@lungcancercanada.ca to aid in shaping access to this therapy.
August 19, 2026 at 6:30 PM
ceceliacare.bsky.social
"Tepmetko ushers in a new era for MET-mutated lung cancer treatment"

#Caregiving #Healthcare #ElderCare #MedSky
Tepmetko ushers in a new era for MET-mutated lung cancer treatment
The treatment of MET-mutated non-small cell lung cancer (NSCLC) is entering a new era, driven by the approval and reimbursement of Tepmetko (ingredient: tepotinib), a targeted therapy that has redefined clinical expectations for a patient population historically underserved by conventional treatment
www.koreabiomed.com
July 29, 2025 at 2:14 PM
infarmed-ip.bsky.social
O medicamento Tepmetko (tepotinib) foi objeto de indeferimento da avaliação prévia hospitalar.
June 18, 2026 at 5:13 PM
bvmurciasalud.bsky.social
#PubSaludMurcia Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping-Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report @Area6VegaMedia
Adding Docetaxel to Tepotinib to Overcome Oligoprogression in MET Exon 14 Skipping–Mutated NSCLC When Local Therapy Is Unfeasible: A Case Report
Oligoprogression in MET Exon 14 skipping (METex14)–mutated non–small cell lung cancer (NSCLC) is clinically challenging, particularly when local therapies are contraindicated. We report the first doc...
doi.org
September 2, 2025 at 1:38 PM
drpushkal.bsky.social
This include cancer medicines including asciminib, pegylated liposomal irinotecan, daratumumab, teclistamab, amivantamab, alectinib, entrectinib, tepotinib, Obinutuzumab, polatuzumab vedotin, atezolizumab, and avelumab.
February 1, 2025 at 2:54 PM
respcasereports.bsky.social
Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
March 2, 2026 at 2:00 AM
respcasereports.bsky.social
Tepotinib-Induced Cholangitis in a Patient With Non-Small Cell Lung Cancer: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
November 25, 2025 at 2:00 AM
respcasereports.bsky.social
Successful #Tepotinib Treatment in MET Exon 14 Skipping Mutation-Positive Lung #Adenocarcinoma With Idiopathic Pulmonary Fibrosis Through #Nintedanib Combination
onlinelibrary.wiley.com/doi/10.1002/...
#IPF
July 7, 2025 at 3:00 AM
onclive.bsky.social
Tepotinib Generates Superior Responses in Adenocarcinoma vs Non-Adenocarcinoma MET Exon 14 Skipping NSCLC @iaslc.bsky.social #WCLC25 #lcsm #oncology www.onclive.com/view/tepotin...
Tepotinib Generates Superior Responses in Adenocarcinoma vs Non-Adenocarcinoma MET Exon 14 Skipping NSCLC
Tepotinib showed superior outcomes in patients with adenocarcinoma MET exon 14 skipping NSCLC vs those with non-adenocarcinoma.
www.onclive.com
September 8, 2025 at 9:25 PM
l2plabs.bsky.social
Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer
Lung cancer is the most common malignancy and leading cause of cancer death globally, with almost 2.5 million new cases and more than 1.8 million deaths due to the disease in 2022 [1,2]. In the United States, it is estimated that 234,580 new lung cancers were diagnosed, and 125,070 lung cancer deaths occurred in 2024 [3]. Approximately 84 % of all lung cancers are non-small cell lung cancer (NSCLC), a heterogeneous disease comprising various histologic subtypes, of which adenocarcinoma is the most common [4].
dlvr.it
July 1, 2025 at 4:25 PM